Review papers with raw data transparency

Detailed Review of 'The complex journey of targeting RAS in oncology'

This review paper addresses a long-standing challenge in oncology: the effective targeting of RAS protein mutations. RAS proteins, particularly KRAS, have been historically considered 'undruggable' due to their high affinity for GTP, lack of deep hydrophobic pockets, and structural similarities between mutant and wild-type forms. The paper summarizes decades of research, highlighting milestones such as the identification of the SW-II pocket and the breakthrough of allele-specific KRAS G12C inhibitors like sotorasib and adagrasib Main RAS targeting review .

Strengths and Contributions

• Comprehensive Synthesis: The paper collates extensive preclinical and clinical data, including molecular dynamics simulations and patient-derived xenograft studies, to present an integrated view of RAS-targeting strategies Integrated data review .
• Discussion on Resistance Mechanisms: A key highlight is the exploration of both on-target resistance (secondary mutations such as Y96D) and off-target resistance (activation of compensatory pathways like PI3K/AKT and up-regulation of receptor tyrosine kinases) which are critical to understanding treatment failures Resistance mechanisms in RAS inhibition .
• Structural Biology Perspective: The discussion is underpinned by structural analyses that reveal important features such as the SW-II pocket, thereby aiding in the rational design of inhibitors. This perspective is supported by additional structural reviews Structural rationale for drug design .

Limitations and Remaining Challenges

The review also acknowledges several critical challenges:

• Adaptive Resistance: The emergence of secondary mutations that impair inhibitor binding and the reactivation of compensatory pathways are major obstacles. These insights suggest that monotherapy may be inadequate, and combination strategies are likely necessary.
• Isoform Selectivity: Despite progress, achieving selective inhibition of mutant RAS over wild-type protein remains a challenge, underlining the need for further refinement in drug design.
• Delivery Issues and Off-target Effects: The review discusses the limitations of current RNA interference and gene-editing strategies, highlighting the necessity for improved delivery systems to mitigate toxicity and off-target effects.

Conclusions and Future Directions

The paper concludes that while significant progress has been made in developing direct and combination therapies for RAS-driven cancers, the complexity of RAS biology demands innovative strategies that integrate structural biology with adaptive resistance analysis. Future research should focus on expanding combination therapies, refining isoform selectivity, and exploring the interplay between RAS and other key regulators such as TP53 Conclusive summary on RAS targeting .

Overall, this review is a valuable resource for researchers focused on precision oncology and the development of novel therapeutic strategies against the RAS signaling pathway.